Form 4: Akebia Therapeutics Director Steven Gilman Receives Equity Compensation Awards

Akebia Therapeutics, Inc. Director Steven C. Gilman was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock on June 10, 2025, as part of the company's non-employee director compensation program.

Summary

• Steven C. Gilman, a Director of Akebia Therapeutics, Inc. (AKBA), received equity awards on June 10, 2025.
• He was granted 35,700 Restricted Stock Units (RSUs) at a price of $0.00.
• These RSUs will vest 100% on the first anniversary of the grant date (June 10, 2026) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• Following this transaction, Mr. Gilman beneficially owns 152,830 shares of common stock.
• Additionally, he was granted options to purchase 53,600 shares of common stock with an exercise price of $3.92, also at a grant price of $0.00.
• These stock options will vest and become exercisable 100% on the first anniversary of the grant date (June 10, 2026) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• The stock options have an expiration date of June 10, 2035.
• Both awards were granted by the Issuer pursuant to its 2023 Stock Incentive Plan and as provided by the company's Fourth Amended and Restated Non-Employee Director Compensation Program.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is a standard practice to align management interests with shareholders. It does not contain any unexpected positive or negative news, thus indicating a neutral to slightly positive sentiment due to the alignment of interests.

Positives

• The grant of equity awards to a director aligns their interests with those of the shareholders, promoting long-term value creation.
• The compensation is part of a pre-existing, disclosed program (Fourth Amended and Restated Non-Employee Director Compensation Program), indicating structured governance.

Future Outlook

The granted Restricted Stock Units and Stock Options are subject to a standard vesting schedule, becoming fully vested on the first anniversary of the grant date or earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, contingent on the reporting person's continued service to the Issuer.

Industry Context

The granting of equity awards, such as restricted stock units and stock options, to non-employee directors is a common and standard practice within the biotechnology and pharmaceutical industries. This approach is widely used to attract and retain qualified board members while aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the compensation against global benchmarks. However, equity grants to non-employee directors are a standard compensation practice across the industry.

Corporate Governance

Related Party Transactions

• The company granted 35,700 Restricted Stock Units and options to purchase 53,600 shares of common stock to Steven C. Gilman, a Director, as part of its Fourth Amended and Restated Non-Employee Director Compensation Program.

Stakeholder Impact

• Shareholders: The equity grants align the director's long-term interests with those of the shareholders, as the value of the awards is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Vesting of the 35,700 Restricted Stock Units on June 10, 2026, or earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.
• Vesting and exercisability of the 53,600 Stock Options on June 10, 2026, or earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

Key Dates

Recommendation

Keywords

Akebia Therapeutics, AKBA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership